Effect of treatment with biological agents for arthritis in Australia: The Australian Rheumatology Association Database

Internal Medicine Journal

Volumn 37, Issue 9, 2007, Pages 591-600

  Buchbinder, R ^a,b,h   March, L ^c,d   Lassere, M ^e,f   Briggs, A M ^a,b   Portek, I ^f   Reid, C ^g   Meehan, A ^g   Henderson, L ^c,d   Wengier, L ^a,b   Van Den Haak, R ^f  

^a CABRINI HOSPITAL   (Australia)

^b Department of Epidemiology and Preventive Medicine ^*  (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f ST GEORGE HOSPITAL   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h CABRINI INSTITUTE   (Australia)

Author keywords

Arthritis; Australia; Biological disease modifying anti rheumatic drug; Health; Registry

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL FACTOR; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD COMPLEX; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE UTILIZATION; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LOWER RESPIRATORY TRACT INFECTION; LUPUS LIKE SYNDROME; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SOCIETY; MELANOMA; META ANALYSIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; AUSTRALIA; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RHEUMATOLOGY; TIME;

EID: 34547897642     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01431.x     Document Type: Article

References (48)

1. Pincus T, Callaghan L. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993 19 : 123 51.
2. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos G. Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life. J Rheumatol 2004 31 : 58 65.
3. Hill CL, Parsons J, Taylor A, Leach G. Health related quality of life in a population sample with arthritis. J Rheumatol 1999 26 : 2029 35.
4. Lassere M, Reitbergan M, Portek I, McGuigan L, Sturgess A, Edmonds J. Mortality and its predictors in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2004 50 : S673.
5. Gordon DA, Hastings DE. Clinical features of rheumatoid arthritis. In : Hochberg M, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology, 3rd edn. London : Mosby 2003.
6. Yelin E. Cost of musculoskeletal diseases: impact of work disability and functional decline. J Rheumatol Suppl 2003 68 : 8 11.
7. Australian Bureau of Statistics. 2001 National Health Survey: Summary of the Results. Canberra : Australian Bureau of Statistics 2002.
8. National Arthritis and Musculoskeletal Conditions Advisory Group (NAMSCAG). Evidence to Support the National Action Plan for Osteoarthritis, Rheumatoid Arthritis and Osteoporosis: Opportunities to Improve Health-Related Quality of Life and Reduce the Burden of Disease and Disability. Canberra : Australian Government Department of Health and Ageing 2004.
9. Pincus T, Gibofsky A, Weinblatt ME. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 2002 46 : 851 4.
10. Weinblatt ME, Keystone EC, Furst DE, Moreland LW et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - the ARMADA trial. Arthritis Rheum 2003 48 : 35 45.
11. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002 46 : 614 24.
12. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999 354 : 1932 9.
13. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al. Etanercept therapy in rheumatoid arthritis - a randomized, controlled trial. Ann Intern Med 1999 130 : 478 86.
14. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 : 2275 85.
15. Dziadzio M, Smith R. Meta-analysis is no substitute for a comprehensive national registry [commentary]. Clin Rheumatol 2006. doi: 10.1007/s10067-006- 0445-5 (Published online).
16. Dixon W, Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and the risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al [commentary]. Arthritis Res Ther 2006 8 : 111.
17. Watson KD, Dixon WG, Hyrich KL, Lunt M, Symmons DPM, Silman AJ. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR biologics register (BSRBR). Rheumatology 2006 45 Suppl i10 i12.
18. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005 352 : 351 61.
19. Lu CY, Williams KM, Day RO. Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target? Intern Med J 2006 36 : 19 27.
20. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003 48 : 313 38.
21. Boyd IW. The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety. Toxicology 2002 181 : 99 102.
22. Australian Drug Reaction Advisory Committee. Department of Health and Ageing: Therapeutic Goods Administration. Commonwealth Government of Australia. Aust Drug React Bull 2006 25 : 1 4.
23. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance - lack of vigilance, lack of trust. JAMA 2004 292 : 2647 50.
24. van Vollenhoven RF, Askling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol 2005 23 Suppl S195 S200.
25. Hetland ML, Unkerskov J, Ravn T, Friis M, Tarp U, Andersen LS et al. Routine database registration of biological therapy increases the reporting of adverse events twenty-fold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol 2005 34 : 40 44.
26. Graves SE, Davidson D, Ingerson L, Ryan P, Griffith EC, McDermott BF et al. The Australian Orthopaedic Association National Joint Replacement Registry. Med J Aust 2004 180 Suppl S31 4.
27. National Health Information Management Group. Minimum Guidelines for Health Registers for Statistical and Research Purposes. Canberra : Australian Institute of Health and Welfare 2001.
28. Lipani JA, Strand C, Woodworth T, Furst D, Singh G, Johnson K et al. A proposal for developing a large population cohort for long term safety monitoring in rheumatoid arthritis. J Rheumatol 2000 27 : 827 30.
29. Wolfe F, Lassere M, van der Heijde D, Stucki G, Suarez-Almazor M, Pincus T et al. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology: consensus report from OMERACT 4. J Rheumatol 1999 26 : 484 9.
30. Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health 2005 29 : 136 42.
31. Watson EK, Firman DW, Baade PD, Ring I. Telephone administration of the SF-36 health survey: validation studies and population norms for adults in Queensland. Aust N Z J Public Health 1996 20 : 359 63.
32. Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the health assessment questionnaire disability index - benchmarking disability in the general population. Arthritis Rheum 2004 50 : 953 60.
33. Kremer J. The CORRONA database. Ann Rheum Dis 2005 64 Suppl iv37 iv41.
34. Silman A, Symmons D, Scott DG, Griffiths I. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003 62 Suppl ii28 ii29.
35. Gomez-Reino JJ, Carmona L, Rodriguez-Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003 48 : 2122 7.
36. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005 52 : 1766 72.
37. Zink A, Huscher D. Longterm studies in rheumatoid arthritis - the German experience. J Rheumatol Suppl 2004 31 : 22 6.
38. Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005 23 Suppl S205 7.
39. Konttinen L, Honkanen V, Uotila T, Pollanen J, Waahtera M, Romu M et al. Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 2006 26 : 916 22.
40. Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005 23 Suppl S188 94.
41. Tubach F, Salmon-Ceron D, Ravaud P, Mariette X, RATIO stuy group. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNF(alpha) therapy. Joint Bone Spine 2005 72 : 456 60.
42. Flendrie M, Creemers MCW, Welsing PMJ, den Broeder AA, van Riel PLCM. Survival drug treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003 62 Suppl 30 33.
43. Kay LJ, Griffiths ID, BSR Biologics Register Management committee. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register. Rheumatology 2006 45 : 1376 9.
44. BIOBADASER Scientific Committee. BIOBADASER Report. Madrid, 2005 Jan.
45. Watson K, Symmons D, Griffiths I, Silman A et al. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005 64 Suppl iv42 iv43.
46. Hjardem E, Hetland ML, Ostergaard M, Krogh NS, Kvien TK. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis 2005 64 : 1220 23.
47. Nordstrom DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S et al. Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int 2006 26 : 741 8.
48. Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rhuem Dis 2005 64 : 246 52.